Vigil Neuroscience, Inc., (VIGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
VIGL Stock Price Chart Interactive Chart >
VIGL Price/Volume Stats
| Current price | $12.00 | 52-week high | $18.27 |
| Prev. close | $12.09 | 52-week low | $2.18 |
| Day low | $11.69 | Volume | 16,549 |
| Day high | $12.49 | Avg. volume | 19,721 |
| 50-day MA | $11.74 | Dividend yield | N/A |
| 200-day MA | $8.43 | Market Cap | 426.97M |
Vigil Neuroscience, Inc., (VIGL) Company Bio
Vigil Neuroscience, Inc., a biotechnology company, discovers and develops novel therapeutics that take advantage of breakthroughs in science and human genetics of microglia. It harnesses the power of microglia for the treatment of neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.
Latest VIGL News From Around the Web
Below are the latest news stories about VIGIL NEUROSCIENCE INC that investors may wish to consider to help them evaluate VIGL as an investment opportunity.
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET. To access a live webcast o |
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases – – Dr. Spyros Papapetropoulos to depart Vigil to pursue a Chief Executive Officer opportunity – CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that David Gray, Ph.D., wi |
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSPFirst-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical needCAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company dosed its first patient in the Phase 2, proof-of-concept clinical trial evaluating VGL101, a ful |
We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company will host an adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) Key Opinion Leader (KOL) event for the investment community in New York City on Tuesday, December 6, 2022, from 8:30 a.m. – 11:30 a.m. ET. The eve |
VIGL Price Returns
| 1-mo | -0.33% |
| 3-mo | 27.93% |
| 6-mo | 51.52% |
| 1-year | -14.71% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -4.00% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...